These data are of high significance, especially taking into account that the interaction of VEGF with RPTPβ/ζ and the downstream angiogenic VEGF actions, such as cell surface NCL localization, do not seem to be affected by existing anti-VEGF drugs, such as bevacizumab, and may explain the resistance developed by tumor types, e.g. glioblastoma, in such therapies [24,41]. This evidence concerns the gene VEGFA and glioblastoma.